Profiling of ileal carcinoids

Neuroendocrinology

Volumn 97, Issue 1, 2013, Pages 7-18

  Nilsson, Ola ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Expression profiling; Genome wide association; Genomic profiling; Ileal carcinoids; Targeted therapy

Indexed keywords

FORODESINE; GAMMA SECRETASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOSTATIN DERIVATIVE; ADRENERGIC RECEPTOR; AMYLOID PRECURSOR PROTEIN; BINDING PROTEIN; BMI1 PROTEIN; CASPASE 4; CASPASE 5; CD47 ANTIGEN; CONNECTIVE TISSUE GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 12P35; INTERLEUKIN 1BETA CONVERTING ENZYME; MICRORNA; OSTEONECTIN; PLATELET DERIVED GROWTH FACTOR; PROCASPASE 8; PROTEIN KINASE C; PROTEIN MDM2; PROTEIN RET; PURINE NUCLEOSIDE PHOSPHORYLASE; SCLEROPROTEIN; SEROTONIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR NKX2.2; TRANSCRIPTION FACTOR RUNX1; TYROSINE KINASE RECEPTOR; VESICULAR MONOAMINE TRANSPORTER 1; ZINC FINGER PROTEIN;

APLP1 GENE; ARTICLE; CANCER RADIOTHERAPY; CARCINOID; CASP1 GENE; CASP4 GENE; CASP5 GENE; CHROMOSOME 11Q; CHROMOSOME 13; CHROMOSOME 14; CHROMOSOME 18; CHROMOSOME 18Q; CHROMOSOME 20; CHROMOSOME 3P; CHROMOSOME 4; CHROMOSOME 5; CHROMOSOME 7; CHROMOSOME DELETION; CHROMOSOME LOSS; COPY NUMBER VARIATION; DAD1 GENE; DOWN REGULATION; ERBB2 GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GPR112 GENE; HUMAN; IL12A GENE; ILEUM CARCINOID; MIR133A GENE; MOLECULARLY TARGETED THERAPY; NK T CELL LYMPHOMA; NONHUMAN; ONCOGENE; OR51E1 GENE; PRIORITY JOURNAL; PRKCA GENE; RET GENE; RISK FACTOR; RUNX1 GENE; RYBP GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SPOCK1 GENE; T CELL LYMPHOMA; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; VMAT1 GENE; CANCER GENETICS; CANCER SUSCEPTIBILITY; GENETIC RISK; ILEAL CARCINOID; ILEUM CANCER; NEUROENDOCRINE TUMOR; REVIEW; SYNAPSE VESICLE; TRANSCRIPTION INITIATION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; ILEUM TUMOR;

CARCINOID TUMOR; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; ILEAL NEOPLASMS;

EID: 84874107023     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000343232     Document Type: Article

References (136)

1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al: One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
2. Ellis L, Shale MJ, Coleman MP: Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gas-troenterol 2010; 105:2563-2569.
3. Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, Kimura W, et al: Epidemiological study of gastroenteropancreatic neuroendo-crine tumors in Japan. J Gastroenterol 2010; 45: 234-243.
4. Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, et al: Neuroendo-crine tumor epidemiology: contrasting Norway and North America. Cancer 2008; 113: 2655-2664.
5. Landerholm K, Falkmer S, Järhult J: Epidemiology of small bowel carcinoids in a defined population. World J Surg 2010; 34: 1500-1505.
6. Berge T, Linell F: Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand A 1976; 84:322-330.
7. Huang LC, Poultsides GA, Norton JA: Surgical management of neuroendocrine tumors of the gastrointestinal tract. Oncology (Wil-liston Park) 2011; 25: 794-803.
8. Pape UF, Perren A, Niederle B, Gross D, Gress T, Costa F, et al: ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012; 95: 135-156.
9. Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, et al: ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95:157-176.
10. Olausson M, Friman S, Herlenius G, Cahlin C, Nilsson O, Jansson S, et al: Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl 2007; 13: 327-333.
11. Modlin IM, Champaneria MC, Chan AK, Kidd M: A three-decade analysis of 3, 911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Am J Gastroen-terol 2007; 102:1464-1473.
12. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-1061.
13. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-4349.
14. Mao X, Young BD, Lu YJ: The application of single nucleotide polymorphism microar-rays in cancer research. Curr Genomics 2007; 8:219-228.
15. Cowell JK, Hawthorn L: The application of microarray technology to the analysis of the cancer genome. Curr Mol Med 2007; 7:103-120.
16. Meyerson M, Gabriel S, Getz G: Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010; 11:685-696.
17. Chung CC, Chanock SJ: Current status of genome-wide association studies in cancer. Hum Genet 2011; 130: 59-78.
18. Babovic-Vuksanovic D, Constantinou CL, Rubin J, Rowland CM, Schaid DJ, Karnes PS: Fami lial occurrence of carcinoid t umors and association with other malignant neoplasms. Cancer Epidemiol Biomarkers Prev 1999; 8: 715-719.
19. Hiripi E, Bermejo JL, Sundquist J, Hemmin-ki K: Familial gastrointestinal carcinoid tumours and associated cancers. Ann Oncol 2009; 20: 950-954.
20. Eschbach JW, Rinaldo JA: Metastatic carci-noid-a familial occurrence. Ann Intern Med 1962; 57: 647-650.
21. Moertel CG, Dockerty MB: Familial occurrence of metastasizing carcinoid tumors. Ann Intern Med 1973; 78:389-390.
22. Wale RJ, Williams JA, Beeley AH, Hughes ES: Familial occurrence in carcinoid tumours. Aust NZ J Surg 1983; 53: 325-328.
23. Pal T, Liede A, Mitchell M, Calender A, Narod SA: Intestinal carcinoid tumours in a father and daughter. Can J Gastroenterol 2001; 15:405-409.
24. Cunningham JL, Diaz de Ståhl T, Sjöblom T, Westin G, Dumanski JP, Janson ET: Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. Genes Chromosomes Cancer 2011; 50: 82-94.
25. Järhult J, Landerholm K, Falkmer S, Norden-skjöld M, Sundler F, Wierup N: First report on metastasizing small bowel carcinoids in first-degree relatives in three generations. Neuroendocrinology 2010; 91:318-323.
26. Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC: Risk factors associated with neuroendocrine tumors: a US-based case-control study. Int J Cancer 2008; 123:867-873.
27. Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC: Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiol Biomarkers Prev 2008; 17:959-965.
28. Hemminki K, Li X: Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden. Int J Cancer 2001; 94: 444-448.
29. Ter-Minassian M, Wang Z, Asomaning K, Wu MC, Liu CY, Paulus JK, et al: Genetic associations with sporadic neuroendocrine tumor risk. Carcinogenesis 2011; 32:1216-1222.
30. Walsh KM, Choi M, Öberg K, Kulke MH, Yao JC, Wu C, et al: A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum. Endocr Relat Cancer 2011; 18: 171-180.
31. Navaglia F, Basso D, Zambon CF, Ponzano E, Caenazzo L, Gallo N, et al: Interleukin-12 gene polymorphisms enhance gastric cancer risk in H. pylori-infected individuals. J Med Genet 2005; 42:503-510.
32. Chen X, Han S, Wang S, Zhou X, Zhang M, Dong J, et al: Interactions of IL-12A and IL-12B polymorphisms on the risk of cervical cancer in Chinese women. Clin Cancer Res 2009; 15:400-405.
33. Liu L, Xu Y, Liu Z, Chen J, Zhang Y, Zhu J, et al: IL-12 polymorphisms, HBV infection and risk of hepatocellular carcinoma in a high-risk Chinese population. Int J Cancer 2012; 128:1692-1696.
34. Sima X, Xu J, Li Q, Luo L, Liu J, You C: Gene-gene interactions between interleukin-12A and interleukin-12B with the risk of brain tumor. DNA Cell Biol 2012; 31:219-223.
35. Nakashima T, Sekiguchi T, Kuraoka A, Fuku-shima K, Shibata Y, Komiyama S, et al: Molecular cloning of a human cDNA encoding a novel protein, DAD1, whose defect causes apoptotic cell death in hamster BHK21 cells. Mol Cell Biol 1993; 13: 6367-6374.
36. Kelleher DJ, Gilmore R: DAD1, the defender against apoptotic cell death, is a subunit of the mammalian oligosaccharyltransferase. Proc Natl Acad Sci USA 1997; 94: 4994-4999.
37. Makishima T, Yoshimi M, Komiyama S, Hara N, Nishimoto T: A subunit of the mammalian oligosaccharyltransferase, DAD1, interacts with Mcl-1, one of the bcl-2 protein fa mily. J Biochem 2000; 128: 399-405.
38. Kulke MH, Freed E, Chiang DY, Philips J, Zahrieh D, Glickman JN, et al: High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. Genes Chromosomes Cancer 2008; 47: 591-603.
39. Tanaka K, Kondoh N, Shuda M, Matsubara O, Imazeki N, Ryo A, et al: Enhanced expression of mRNAs of antisecretory factor-1, gp96, DAD1 and CDC34 in human hepato-cellular carcinomas. Biochim Biophys Acta 2001; 1536: 1-12.
40. Kim YH, Girard L, Giacomini CP, Wang P, Hernandez-Boussard T, Tibshirani R, et al: Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene 2006; 25: 130-138.
41. True L, Coleman I, Hawley S, Huang CY, Gif-ford D, Coleman R, et al: A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA 2006; 103: 10991-10996.
42. Trempat P, Villalva C, Xerri L, Armstrong F, Duplantier M M, Delsol G, et al: Geneexpression profiling in anaplastic large cell lym-phoma and Hodgkin's disease. Leuk Lym-phoma 2004; 45:2001-2006.
43. Yoon J, Kim ES, Lee SJ, Park CW, Cha HJ, Hong BH, et al: Apoptosis-related mRNA expression profiles of ovarian cancer cell lines following cisplatin treatment. J Gynecol Oncol 2010; 21:255-261.
44. Wei G, Margolin AA, Haery L, Brown E, Cu-colo L, Julian B, et al: Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell 2012; 21:547-562.
45. Rath O, Kozielski F: Kinesins and cancer. Nat Rev Cancer 2012; 12: 527-539.
46. Carlucci A, Porpora M, Garbi C, Galgani M, Santoriello M, Mascolo M, et al: PTPD1 supports receptor stability and mitogenic signaling in bladder cancer cells. J Biol Chem 2010; 285:39260-39270.
47. Ueno H, Huang X, Tanaka Y, Hirokawa N: KIF16B/Rab14 molecular motor complex is critical for early embryonic development by transporting FGF receptor. Dev Cell 2011; 20: 60-71.
48. Coetzee GA, Jia L, Frenkel B, Henderson BE, Tanay A, Haiman CA, et al: A systematic approach to understand the functional consequences of non-protein coding risk regions. Cell Cycle 2010; 9: 256-259.
49. Galvan A, Ioannidis JP, Dragani TA: Beyond genome-wide association studies: genetic heterogeneity and individual predisposition to cancer. Trends Genet 2010; 26: 132-141.
50. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al: Finding the missing heritability of complex diseases. Nature 2009; 461:747-753.
51. Sjögren H, Nilsson O, Behrendt M, Kölby L, Jacobsen Levin AM, Ahlman H, et al: Multicolor spectral karyotype analysis of a trans-plantable human ileal carcinoid. Int J Mol Med 2000; 6: 629-633.
52. Van Buren G 2nd, Rashid A, Yang AD, Ab-dalla EK, Gray MJ, Liu W, et al: The development and characterization of a human mid-gut carcinoid cell line. Clin Cancer Res 2007; 13: 4704-4712.
53. Pfragner R, Behmel A, Hoger H, Beham A, Ingolic E, Stelzer I, et al: Establishment and characterization of three novel cell lines-P-STS, L-STS, H-STS-derived from a human metastatic midgut carcinoid. Anticancer Res 2009; 29: 1951-1961.
54. Löllgen RM, Hessman O, Szabo E, Westin G, Åkerström G: Chromosome 18 deletions are common events in classical midgut carci-noid tumors. Int J Cancer 2001; 92: 812-815.
55. Stancu M, Wu TT, Wallace C, Houlihan PS, Hamilton SR, Rashid A: Genetic alterations in goblet cel l carcinoids of t he vermiform appendix and comparison with gastrointestinal carcinoid tumors. Mod Pathol 2003; 16: 1189-1198.
56. Wang GG, Yao JC, Worah S, White JA, Luna R, Wu TT, et al: Comparison of genetic alterations in neuroendocrine tumors: frequent loss of chromosome 18 in ileal carci-noid tumors. Mod Pathol 2005; 18: 1079-1087.
57. Katona TM, Jones TD, Wang M, Abdul-Karim FW, Cummings OW, Cheng L: Molecular evidence for independent origin of multifocal neuroendocrine tumors of the enteropancre-atic axis. Cancer Res 2006; 66: 4936-4942.
58. Terris B, Meddeb M, Marchio A, Danglot G, Flejou JF, Belghiti J, et al: Comparative ge-nomic hybridization analysis of sporadic neuroendocrine tumors of the digestive system. Genes Chromosomes Cancer 1998; 22: 50-56.
59. Kytölä S, Höög A, Nord B, Cedermark B, Frisk T, Larsson C, et al: Comparative ge-nomic hybridization identifies loss of 18q22-qter as an early and specific event in tumori-genesis of midgut carcinoids. Am J Pathol 2001; 158:1803-1808.
60. Tönnies H, Toliat MR, Ramel C, Pape UF, Neitzel H, Berger W, et al: Analysis of sporadic neuroendocrine tumours of the entero-pancreatic system by comparative genomic hybridisation. Gut 2001; 48: 536-541.
61. Kimdo H, Nagano Y, Choi IS, White JA, Yao JC, Rashid A: Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors. Genes Chromosomes Cancer 2008; 47: 84-92.
62. Chan AO, Kim SG, Bedeir A, Issa JP, Hamilton SR, Rashid A: CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 2003; 22:924-934.
63. Gilbert JA, Adhikari LJ, Lloyd RV, Rubin J, Haluska P, Carboni JM, et al: Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. Endocr Relat Cancer 2010; 17: 623-636.
64. Haughian JM, Reno EM, Thorne AM, Bradford AP: Protein kinase Ca-dependent signaling mediates endometrial cancer cell growth and tumorigenesis. Int J Cancer 2009; 125: 2556-2564.
65. Kim J, Thorne SH, Sun L, Huang B, Mochly-Rosen D: Sustained inhibition of PKCa reduces intravasation and lung seeding during mammary tumor metastasis in an in vivo mouse model. Oncogene 2011; 30:323-333.
66. Lonne GK, Cornmark L, Zahirovic IO, Landberg G, Jirström K, Larsson C: PKCa expression is a marker for breast cancer aggressiveness. Mol Cancer 2010; 9: 76.
67. Smith SD, Enge M, Bao W, Thullberg M, Costa TD, Olofsson H, et al: Protein kinase Ca regulates p53 localisation and melanoma cell survival downstream of integrin av in 3D-collagen and in vivo. J Biol Chem 2012; 287: 29336-29347.
68. Villalona-Calero MA, Ritch P, Figueroa JA, Otterson GA, Belt R, Dow E, et al: A phase I/II study of LY900003, an antisense inhibitor of protein kinase Ca, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004; 10: 6086-6093.
69. Paz-Ares L, Douillard JY, Koralewski P, Ma-negold C, Smit EF, Reyes JM, et al: Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase Ca antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2006; 24:1428-1434.
70. Andersson E, Swärd C, Stenman G, Ahlman H, Nilsson O: High-resolution genomic pro-filing reveals gain of chromosome 14 as a predictor of poor outcome in ileal carcinoids. Endocr Relat Cancer 2009; 16: 953-966.
71. Danen-van Oorschot AA, Voskamp P, Seelen MC, van Miltenburg MH, Bolk MW, Tait SW, et al: Human death effector domain-associated factor interacts with the viral apop-tosis agonist apoptin and exerts tumor-preferential cell killing. Cell Death Differ 2004; 11: 564-573.
72. Neira JL, Roman-Trufero M, Contreras LM, Prieto J, Singh G, Barrera FN, et al: The transcriptional repressor RYBP is a natively unfolded protein which folds upon binding to DNA. Biochemistry 2009; 48: 1348-1360.
73. Chen D, Zhang J, Li M, Rayburn ER, Wang H, Zhang R: RYBP stabilizes p53 by modu-lat ing MDM2. EMBO Rep 2009; 10: 166-172.
74. Tavares L, Dimitrova E, Oxley D, Webster J, Poot R, Demmers J, et al: RYBP-PRC1 complexes mediate H2A ubiquitylation at poly-comb target sites independently of PRC2 and H3K27me3. Cell 2012; 148:664-678.
75. Taylor BS, Schultz N, Hieronymus H, Gopa-lan A, Xiao Y, Carver BS, et al: Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
76. Lando M, Holden M, Bergersen LC, Svends-rud DH, Stokke T, Sundfor K, et al: Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer. PLoS Genet 2009; 5:e1000719.
77. Novak RL, Phillips AC: Adenoviral-mediat-ed Rybp expression promotes tumor cell-specific apoptosis. Cancer Gene Ther 2008; 15: 713-722.
78. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, et al: Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000; 287:848-851.
79. Kytölä S, Nord B, Elder EE, Carling T, Kjell-man M, Cedermark B, et al: Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocyto-mas, and abdominal paragangliomas. Genes Chromosomes Cancer 2002; 34: 325-332.
80. Gilbert JA, Bates LA, Ames MM: Elevated aromatic-L-amino acid decarboxylase in human carcinoid tumors. Biochem Pharmacol 1995; 50:845-850.
81. O'Connor DT, Deftos LJ: Secretion of chro-mogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986; 314: 1145-1151.
82. Jakobsen AM, Ahlman H, Wängberg B, Köl-by L, Bengtsson M, Nilsson O: Expression of synaptic vesicle protein 2 (SV2) in neuroen-docrine tumours of the gastrointestinal tract and pancreas. J Pathol 2002; 196: 44-50.
83. Jakobsen AM, Andersson P, Saglik G, An-dersson E, Kölby L, Erickson JD, et al: Differential expression of vesicular monoamine transporter (VMAT) 1 and 2 in gastrointestinal endocrine tumours. J Pathol 2001; 195: 463-472.
84. Reubi JC, Kvols LK, Waser B, Nagorney DM, Heitz PU, Charboneau JW, et al: Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carci-noids and islet cell carcinomas. Cancer Res 1990; 50:5969-5977.
85. Nilsson O, Kölby L, Wängberg B, Wigander A, Billig H, William-Olsson L, et al: Comparative studies on the expression of so-matostatin receptor subtypes, outcome of octreotide scintigraphy and response to oc-treotide treatment in patients with carcinoid tumours. Br J Cancer 1998; 77:632-637.
86. Modlin IM, Kidd M, Pfragner R, Eick GN, Champaneria MC: The functional characterization of normal and neoplastic human enterochromaffin cells. J Clin Endocrinol Metab 2006; 91: 2340-2348.
87. Wang YC, Zuraek MB, Kosaka Y, Ota Y, German MS, Deneris ES, et al: The ETS onco-gene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine. Endocr Relat Cancer 2010; 17:283-291.
88. Saqi A, Alexis D, Remotti F, Bhagat G: Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carci-noids. Am J Clin Pathol 2005; 123: 394-404.
89. Wang YC, Gallego-Arteche E, Iezza G, Yuan X, Matli MR, Choo SP, et al: Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors. Endocr Relat Cancer 2009; 16: 267-279.
90. 3] octreo-tate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-2130.
91. Duerr EM, Mizukami Y, Ng A, Xavier RJ, Ki-kuchi H, Deshpande V, et al: Defining molecular classifications and targets in gastro-enteropancreatic neuroendocrine tumors through DNA microarray analysis. Endocr Relat Cancer 2008; 15:243-256.
92. Fujiki K, Duerr EM, Kikuchi H, Ng A, Xavier RJ, Mizukami Y, et al: Hoxc6 is overexpressed in gastrointestinal carcinoids and interacts with JunD to regulate tumor growth. Gastro-enterology 2008; 135: 907-916, 16 e1-2.
93. Han Z, Ni J, Smits P, Underhill CB, Xie B, Chen Y, et al: Extracellular matrix protein 1 (ECM1) has angiogenic properties and is expressed by breast tumor cells. FASEB J 2001; 15:988-994.
94. Lal G, Hashimi S, Smith BJ, Lynch CF, Zhang L, Robinson RA, et al: Extracellular matrix 1 (ECM1) expression is a novel prognostic marker for poor long-term survival in breast cancer: a hospital-based cohort study in Iowa. Ann Surg Oncol 2009; 16:2280-2287.
95. Wu QW, She HQ, Liang J, Huang YF, Yang QM, Yang QL, et al: Expression and clinical significance of extracellular matrix protein 1 and vascular endothelial growth factor-C in lymphatic metastasis of human breast cancer. BMC Cancer 2012; 12:47.
96. Chen H, Jia WD, Li JS, Wang W, Xu GL, Ma JL, et al: Extracellular matrix protein 1, a novel prognostic factor, is associated with meta-static potential of hepatocellular carcinoma. Med Oncol 2011; 28(suppl 1):S318-S325.
97. Bergamaschi A, Tagliabue E, Sorlie T, Nau-me B, Triulzi T, Orlandi R, et al: Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol 2008; 214:357-367.
98. Druce M, Rockall A, Grossman AB: Fibrosis and carcinoid syndrome: from causation to future therapy. Nat Rev Endocrinol 2009; 5:276-283.
99. Chaudhry A, Papanicolaou V, Oberg K, Heldin CH, Funa K: Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res 1992; 52:1006-1012.
100. Kidd M, Modlin IM, Shapiro MD, Camp RL, Mane SM, Usinger W, et al: CTGF, intestinal stellate cells and carcinoid fibro-genesis. World J Gastroenterol 2007; 13: 5208-5216.
101. Kölby L, Bernhardt P, Levin-Jakobsen AM, Johanson V, Wängberg B, Ahlman H, et al: Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. Br J Cancer 2003; 89: 1383-1388.
102. Nikiforov YE, Nikiforova MN: Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011; 7: 569-580.
103. Frank-Raue K, Rondot S, Raue F: Molecular genetics and phenomics of RET mutations: impact on prognosis of MTC. Mol Cell Endocrinol 2010; 322:2-7.
104. Antonelli A, Fallahi P, Ferrari SM, Mancu-si C, Colaci M, Santarpia L, et al: RET TKI: potential role in thyroid cancers. Curr Oncol Rep 2012; 14:97-104.
105. Phay JE, Shah MH: Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res 2010; 16: 5936-5941.
106. Chan JA, Kulke MH: New treatment options for patients with advanced neuroendocrine tumors. Curr Treat Options Oncol 2011; 12: 136-148.
107. Arvidsson Y, Andersson E, Bergström A, Andersson MK, Altiparmak G, Illerskog AC, et al: Amyloid precursor-like protein 1 is differentially upregulated in neuroendocrine tumours of the gastrointestinal tract. Endocr Relat Cancer 2008; 15: 569-581.
108. De Strooper B, Annaert W: Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci 2000; 113:1857-1870.
109. Scheinfeld MH, Ghersi E, Laky K, Fowlkes BJ, DAdamio L: Processing of fS-amyloid precursor-like protein-1 and-2 by 7-secre-tase regulates transcription. J Biol Chem 2002; 277:44195-44201.
110. Paliga K, Peraus G, Kreger S, Durrwang U, Hesse L, Multhaup G, et al: Human amyloid precursor-like protein 1-cDNA cloning, ectopic expression in COS-7 cells and identification of soluble forms in the cerebrospinal fluid. Eur J Biochem 1997; 250: 354-363.
111. Adlerz L, Beckman M, Holback S, Tehra-nian R, Cortes Toro V, Iverfeldt K: Accumulation of the amyloid precursor-like protein APLP2 and reduction of APLP1 in retinoic acid-differentiated human neuroblastoma cells upon curcumin-induced neurite retraction. Brain Res Mol Brain Res 2003; 119: 62-72.
112. Adlerz L, Holback S, Multhaup G, Iverfeldt K: IGF-1-induced processing of the amyloid precursor protein family is mediated by different signaling pathways. J Biol Chem 2007; 282:10203-10209.
113. Von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, et al: Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 2000; 60:4573-4581.
114. Nilsson O, Wängberg B, Theodorsson E, Skottner A, Ahlman H: Presence of IGF-I in human midgut carcinoid tumours-an autocrine regulator of carcinoid tumour growth? Int J Cancer 1992; 51: 195-203.
115. Hansel DE, Rahman A, Wehner S, Herzog V, Yeo CJ, Maitra A: Increased expression and processing of the Alzheimer amyloid precursor protein in pancreatic cancer may influence cellular proliferation. Cancer Res 2003; 63:7032-7037.
116. Paris D, Quadros A, Patel N, DelleDonne A, Humphrey J, Mullan M: Inhibition of an-giogenesis and tumor growth by fS-and 7-secretase inhibitors. Eur J Pharmacol 2005; 514: 1-15.
117. Mizuma M, Rasheed ZA, Yabuuchi S, Omura N, Campbell NR, de Wilde RF, et al: The 7-secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models. Mol Cancer Ther 2012; 11: 1999-2009.
118. Leja J, Essaghir A, Essand M, Wester K, Öberg K, Tötterman TH, et al: Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Mod Pathol 2009; 22: 261-272.
119. Wlazlinski A, Engers R Hoffmann MJ, Hader C, Jung V, Muller M, et al: Down-regulation of several fibulin genes in prostate cancer. Prostate 2007; 67:1770-1780.
120. Schulz WA, Ingenwerth M, Djuidje CE, Hader C, Rahnenfuhrer J, Engers R: Changes in cortical cytoskeletal and extracellular matrix gene expression in prostate cancer are related to oncogenic ERG deregulation. BMC Cancer 2010; 10:505.
121. Ruebel K, Leontovich AA, Stilling GA, Zhang S, Righi A, Jin L, et al: MicroRNA expression in ileal carcinoid tumors: down-regulation of microRNA-133a with tumor progression. Mod Pathol 2010; 23: 367-375.
122. Nohata N, Hanazawa T, Enokida H, Seki N: microRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers. Oncotarget 2012; 3: 9-21.
123. Suzuki S, Yokobori T, Tanaka N, Sakai M, Sano A, Inose T, et al: CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. Oncol Rep 2012; 28:465-472.
124. Tse EY, Ko FC, Tung EK, Chan LK, Lee TK, Ngan ES, et al: Caveolin-1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis. J Pathol 2012; 226: 645-653.
125. Nohata N, Hanazawa T, Kikkawa N, Mutal-lip M, Fujimura L, Yoshino H, et al: Caveolin-1 mediates tumor cell migration and invasion and its regulation by miR-133a in head and neck squamous cell carcinoma. Int J Oncol 2011; 38:209-217.
126. Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, et al: miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 2010; 127: 2804-2814.
127. Stetak A, Veress R, Ovadi J, Csermely P, Keri G, Ullrich A: Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res 2007; 67:1602-1608.
128. Kojima S, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nohata N, et al: Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase in prostate cancer. Br J Cancer 2012; 106:405-413.
129. Traenka C, Remke M, Korshunov A, Bender S, Hielscher T, Northcott PA, et al: Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medullo-blastoma. Cancer Res 2010; 70:8003-8014.
130. Ogura M, Tsukasaki K, Nagai H, Uchida T, Oyama T, Suzuki T, et al: Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies. Cancer Sci 2012, E-pub ahead of print.
131. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, et al: The CD47-signal regulatory protein a (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 2012; 109:6662-6667.
132. Edfeldt K, Björklund P, Åkerström G, Wes-tin G, Hellman P, Stålberg P: Different gene expression profiles in metastasizing midgut carcinoid tumors. Endocr Relat Cancer 2011; 18: 479-489.
133. Ito Y: Oncogenic potential of the RUNX gene family: 'overview'. Oncogene 2004; 23: 4198-4208.
134. Hoi CS, Lee SE, Lu SY, McDermitt DJ, Oso-rio KM, Piskun CM, et al: Runx1 directly promotes proliferation of hair follicle stem cells and epithelial tumor formation in mouse skin. Mol Cell Biol 2010; 30:2518-2536.
135. Gaidzik VI, Bullinger L, Schlenk RF, Zim-mermann AS, Rock J, Paschka P, et al: RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol 2011; 29:1364-1372.
136. Gaur P, Sceusi EL, Samuel S, Xia L, Fan F, Zhou Y, et al: Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology 2011; 141:1728-1737.